AIM: Improvement of EFS of children older than 3 years with high risk medulloblastoma. METHODS: Between 1993 and 1999, 115 patients (3-18 years, mean 8 years) with high risk medulloblastoma were included. After surgery treatment consisted of chemotherapy ('8in1' and etoposide/carboplatin) before and after craniospinal radiotherapy. RESULTS: Patients were staged using Chang-criteria (PF residue only, M1 and M2/M3) by local investigator as well as by central review panel (82.4% concordance). Chemotherapy was well tolerated without major delays in radiotherapy. With a mean follow up of 81 months (9-119), 5-year EFS was 49.8% and OS 60.1%. In detail according to subgroups EFS was 68.8% for PF residue only, 58.8% for M1 disease and 43.1% for M2/M3. CONCLUSION: M1 patients are legitimate high risk patients. Survival rates are still very low for high risk medulloblastoma patients and future trials should therefore focus on more intensive (chemotherapy/radiotherapy) treatment.
AIM: Improvement of EFS of children older than 3 years with high risk medulloblastoma. METHODS: Between 1993 and 1999, 115 patients (3-18 years, mean 8 years) with high risk medulloblastoma were included. After surgery treatment consisted of chemotherapy ('8in1' and etoposide/carboplatin) before and after craniospinal radiotherapy. RESULTS:Patients were staged using Chang-criteria (PF residue only, M1 and M2/M3) by local investigator as well as by central review panel (82.4% concordance). Chemotherapy was well tolerated without major delays in radiotherapy. With a mean follow up of 81 months (9-119), 5-year EFS was 49.8% and OS 60.1%. In detail according to subgroups EFS was 68.8% for PF residue only, 58.8% for M1 disease and 43.1% for M2/M3. CONCLUSION: M1 patients are legitimate high risk patients. Survival rates are still very low for high risk medulloblastomapatients and future trials should therefore focus on more intensive (chemotherapy/radiotherapy) treatment.
Authors: Paul L Moots; Anne O'Neill; Harold Londer; Minesh Mehta; Deborah T Blumenthal; Geoffrey R Barger; Margaret L Grunnet; Stuart Grossman; Mark R Gilbert; David Schiff Journal: Am J Clin Oncol Date: 2018-06 Impact factor: 2.339
Authors: Adam J Esbenshade; Mehmet Kocak; Linda Hershon; Pierre Rousseau; Jean-Claude Decarie; Susan Shaw; Peter Burger; Henry S Friedman; Amar Gajjar; Albert Moghrabi Journal: Pediatr Blood Cancer Date: 2016-12-21 Impact factor: 3.167
Authors: Luc Le Fournier; Matthieu Delion; Maxime Esvan; Emilie De Carli; Céline Chappé; Philippe Mercier; Philippe Menei; Laurent Riffaud Journal: Childs Nerv Syst Date: 2017-05-11 Impact factor: 1.475
Authors: Jing-Jing Liu; Yan-Ling Sun; Shu-Xu DU; Chun-De Li; Xiao-Jun Gong; Miao Li; Wan-Shui Wu; Li-Ming Sun Journal: Zhongguo Dang Dai Er Ke Za Zhi Date: 2019-08
Authors: Alessandra Rossi; Valentina Caracciolo; Giuseppe Russo; Krzysztof Reiss; Antonio Giordano Journal: Clin Cancer Res Date: 2008-02-15 Impact factor: 12.531
Authors: Sun Young Kim; Ki Woong Sung; Jeong Ok Hah; Keon Hee Yoo; Hong Hoe Koo; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn; Ho Joon Im; Jong Jin Seo; Yeon Jung Lim; Young Ho Lee; Hyung Jin Shin; Do Hoon Lim; Byung Kyu Cho; Young Shin Ra; Joong Uhn Choi Journal: Korean J Hematol Date: 2010-06-30
Authors: P Frange; C Alapetite; G Gaboriaud; D Bours; J M Zucker; M Zerah; H Brisse; M Chevignard; V Mosseri; E Bouffet; F Doz Journal: J Neurooncol Date: 2009-06-12 Impact factor: 4.130